摘要
目的:观察制霉菌素联合伊曲康唑治疗假丝酵母菌外阴阴道疾病(VVC)的临床疗效和安全性。方法:84例VVC的女性患者按随机数字表法均分为对照组和观察组。对照组患者给予伊曲康唑胶囊0.4 g,口服,bid;观察组患者在对照组治疗的基础上给予制霉菌素阴道栓剂1枚,于每晚休息前置入阴道深部,qd。两组患者疗程均为7 d。观察两组患者的临床疗效,治疗前后临床症状总评分、阴道分泌物细菌数及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05)。治疗前两组患者临床症状总评分、阴道分泌物细菌数比较,差异均无统计学意义(P>0.05);治疗后两组患者临床症状总评分、阴道分泌物细菌数均显著低于同组治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:制霉菌素联合伊曲康唑治疗VVC较单用伊曲康唑疗效更好,安全性较好。
OBJECTIVE ： To observe clinical efficacy and safety of nystatin combined with itraconazole in the treatment of Can- dida vulvovaginal vagina disease （VVC）. METHODS： 84 female patients with VVC were randomly divided into control group and observation group. Control group was given Itraconazole capsules 0.4 g orally, 2 times/d; observation group was additionally treat- ed with Nystatin vaginal suppository, inserting into the vagina depth portion before going to bed at night. Therapeutic efficacies of 2 groups lasted for 7 d. The clinical efficacies of 2 groups were observed, and total clinical symptom score, the number of vaginal bacteria and ADR were observed before and after treatment. RESULTS： The total effective rate of observation group were signifi- cantly higher than that of control group, there was significant difference between 2 groups （P〈0.05）. There was no statistical sig- nificance in the total clinical symptom score and vaginal bacterial count between 2 groups before treatment （P 〉 0.05） ; total clinical symptom score and vaginal bacterial count of 2 groups after treatment were significantly lower than before; the observation group was lower than the control group; there was statistical significance （P〈0.05）. No obvious ADR was found in 2 groups during treat- ment. CONCLUSIONS： Nystatin combined with itraconazole is better than itraconazole alone in the treatment of VVC in therapeu- tic efficacy and safety.
出处
《中国药房》
CAS
CSCD
2014年第40期3770-3772,共3页
China Pharmacy
